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Abstract
Background Viral myocarditis can severely damage the
myocardium through excessive infiltration of immune
cells. Osteoglycin (OGN) is part of the small leucine-rich
repeat proteoglycan (SLRP) family. SLRP’s may affect
inflammatory and fibrotic processes, but the implication of
OGN in cardiac inflammation and the resulting injury upon
viral myocarditis is unknown.
Methods and results This study uncovered a previously
unidentified 72-kDa variant of OGN that is predominant in
cardiac human and mouse samples of viral myocarditis. Its
absence in mice significantly decreased cardiac inflammation
and injury in Coxsackievirus-B3-induced myocarditis. It also
delayed mortality in lipopolysaccharide-induced endotox-
emia going along with a reduced systemic production of pro-
inflammatory cytokines.This 72-kDaOGN is expressed in the
cell membrane of circulating and resident cardiac macro-
phages and neutrophils. Co-immunoprecipitation and OGN
siRNA experiments revealed that this 72-kDa variant acti-
vates the toll-like receptor-4 (TLR4) with a concomitant
increase in IL-6, TNF-a, IL-1b, and IL-12 expression. This
immune cell activation by OGN occurred via MyD88 and
increased phosphorylation of c-jun. Finally, the 72-kDa
chondroitin sulfate is the result of O-linked glycosylation of
the 32-kDa protein core of OGN. In contrast, the 34-kDa
dermatan sulfate-OGN, involved in collagen cross linking,
was also the result of O-linked glycosylation.
Conclusion The current study discovered a novel 72-kDa
chondroitin sulfate-OGN that is specific for innate immune
cells. This variant is able to bind and activate TLR4. The
absence of OGN decreases cytokine production by both
circulating and cardiac leukocytes upon (systemic) LPS
exposure, and reduces cardiac inflammation and injury in
viral myocarditis.
Keywords Glycosylation  TLR4  Osteoglycin 
Inflammation  Viral myocarditis
Introduction
Osteoglycin (OGN) belongs to the small leucine-rich pro-
teoglycan (SLRP) family of proteins, which also includes
biglycan and decorin. These SLRPs are well known for their
well-timed action on shaping the architecture and organi-
zation of collagen-rich extracellular matrices in the heart and
other organs. OGN is critical during the wound healing
process after myocardial infarction by stimulating the for-
mation of well-aligned collagen fibers in the infarct scar [1].
Some matrix components, proteoglycans, and glycoproteins
have been recognized for regulating inflammation in organs
outside the heart [2]; however, no such role has been
described for OGN in either the heart or other organs. Fur-
thermore, OGN is a proteoglycan and is, therefore, subject to
glycosylation, a post-translation modification that adds gly-
cosaminoglycans and glycans to proteins in the endoplasmic
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reticulum and Golgi apparatus, diversifying protein function
[2]. While OGN requires glycosaminoglycan keratan sulfate
for corneal transparency [3, 4], no clear-cut and compre-
hensive description of all potential glycosylation variants is
available. Moreover, nothing is known about the glycosy-
lation state of OGN during different forms of cardiac
diseases and the impact of this glycosylation on cardiac
inflammation or fibrosis.
Adverse cardiac inflammation and damage upon viral
infection, followed by adverse remodeling, is an important
cause of heart failure and sudden cardiac death in previously
healthy individuals [5]. Understanding how the immune
system responds to various endangering stimuli (ischemia
versus viruses) might clarify the contribution of the inflam-
matory response to adverse cardiac remodeling and hence
lead to the discovery of specific therapeutic strategies. The
need for new specific therapeutic strategies is underlined by
the poor prognosis once heart failure becomes chronic [6].
Here, we discovered that SLRP OGN can be differen-
tially glycosylated depending on the underlying
pathophysiology, inflammation (myocarditis) versus
fibrosis (myocardial infarction). Here, we link the OGN-
dermatan sulfate (34 kDa) predominantly to cardiac fibro-
sis, while the previously unknown OGN-chondroitin
sulfate (72 kDa) prevails in the cell membrane of both
murine and human leukocytes and is thus linked to
inflammation. We unveil that this 72-kDa inflammatory
variant binds to TLR4 and enhances its activation. As such,
increased OGN results in exaggerated innate immune
responses in both endotoxemia and viral myocarditis.
Results
Different OGN variants are present in different
cardiac pathologies
First, protein expression of OGN was studied in murine
hearts 7 days after intraperitoneal injection of Coxsackie B3
virus (CVB3). The sole presence of a new yet undescribed
cardiac OGN variant of approximately 72-kDa was found in
the murine hearts with viral myocarditis (Fig. 1a).
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Fig. 1 Murine and human tissues express different OGN variants in
distinct cardiac diseases. a Western blot analysis for OGN revealed a
small variant (34 kDa) in murine myocardial infarction, whereas in
murine viral myocarditis, a large variant (72 kDa) was present
(n C 4). b Western blot analysis of cardiac tissues of mice 7 days
after viral exposure was compared with healthy controls and
quantified. Viral infection led to increased expression of a
70–72 kDa OGN variant compared with healthy controls (sham
n = 3, VM n = 5, *p\ 0.05). c Differential expression of the main
OGN variants in various healthy murine tissues. d Western blot
analysis for OGN in human ischemic myocardial tissue showing
increased expression of the large (72 kDa) and the small (34 kDa)
OGN variants relative to those in the control cardiac tissue. e Human
buffy coat revealed a similar presence of the OGN variants with high
abundance of the 72-kDa variant, which was barely detectable in
human splenic tissues
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Contrarily, a 34-kDa OGN variant was highly abundant in
murine myocardial infarcts (Fig. 1a), temporally and spa-
tially associated with collagen fibrillogenesis [7, 8].
Expression of this 72-kDa protein variant increased signifi-
cantly in the hearts of WT mice after inoculation with CVB3
compared with healthy controls (Fig. 1b). When further
analyzing OGN protein expression in different tissues, we
identified very distinct yet consistent glycosylation patterns.
Murine corneal tissues had a high abundance of the 50-kDa
keratan sulfate variant [3] which is in line with literature
findings. Tissues with high collagen and connective tissue
contents, such as bone, tail, and skin, presented with the
34-kDa variant (Fig. 1c). Furthermore, human tissue and
blood samples demonstrated a comparable occurrence of the
OGN protein variants. In post-mortem left ventricular tissues
from ischemic patients in which the collagen content, as a
consequence of scaring and fibrosis, is high, mainly the
34-kDa OGN variant was detected, while it could not be
found in control patients without scaring (Fig. 1d). This is
supported by immunohistochemical staining for OGN in
human myocardial infarcts, revealing that OGN staining
clearly matched cardiac fibrosis [9]. In sharp contrast, the
72-kDa variant was highly expressed on human circulating
leukocytes (Fig. 1e), whereas it could not be detected in
post-mortem splenic tissue (Fig. 1d). Therefore, we
hypothesized that the presence of distinct OGN variants may
be associated with the specific underlying pathophysiologi-
cal processes, reactive to an environmental pathogen. In
viral myocarditis patients, where there is both fibrosis and
inflammation [10], we identified an increase in OGN stain-
ing compared with control hearts (Fig. 2a, b). Here, positive
OGN staining was found in areas with fibrosis (Fig. 2c) but
also on immune cells (Fig. 2d). Correspondingly, in our
murine model of CVB3 myocarditis, where inflammation is
present, but fibrosis is not [11], OGN staining predominated
on leukocytes (Fig. 2e). Consequently, the observed varia-
tion in size of this proteoglycan in relation to either cardiac
fibrosis (34-kDa) or cardiac inflammation (72-kDa) led us to
conclude that differential glycosylation may be in control.
OGN is present on cardiac and circulating innate
immune cells
As the 72-kDa ‘inflammatory’ OGN (iOGN) was primarily
found in viral myocarditis on leukocytes, we further ana-
lyzed its specific expression in circulatory leukocytes
versus cardiac leukocytes using immunofluorescence and
flow cytometry in both mice and humans. OGN clearly co-
stained with both murine neutrophil (Gr1)- and mono-
cyte/macrophage (Mac3)-markers in the myocardium
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Fig. 2 Different OGN variants are correlated with fibrosis and
inflammation in murine and human cardiac diseases. a Increased
immunohistochemical OGN staining was found in patients diagnosed
with myocarditis. b Quantification of OGN staining in patients
diagnosed with myocarditis (n C 14). c OGN expression in human
myocarditis biopsies coincided with fibrosis as shown by Sirius red
staining. d OGN staining was also found on leukocytes in human
myocarditis biopsies as well as in the hearts of mice subjected to
CVB3-induced myocarditis. e Immunofluorescence demonstrated the
co-localization of OGN with CD45? leukocytes in the hearts of mice
subjected to virus myocarditis compared with healthy controls (scale
bar healthy controls: 20 lm). All experiments were repeated at least
twice. Scale bar 50 lm. VM viral myocarditis, MI myocardial
infarction
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(Fig. 3a). To verify that the relevance of OGN was not
exclusive for mice, we confirmed its occurrence on circu-
lating human leukocytes, the source for cardiac
inflammation in response to CVB3 infection. Human
peripheral leukocytes in blood smears and buffy coats
demonstrated a similar co-localization of OGN with human
peripheral neutrophil- and monocyte-markers (Fig. 3b).
Separating OGN-positive peripheral leukocytes (OGN
?ve) from the total circulating peripheral leukocytes using
OGN-bound magnetic Dynabeads allowed us to better
identify the OGN expressing circulating immune cell
population by FACS analysis. As approximately 50–70%
of all human circulating leukocytes are composed of neu-
trophils, FACS analyses revealed the presence of OGN
predominantly on peripheral neutrophils (Fig. 3c–e).
Interestingly, these circulating iOGN-positive leukocytes
showed significantly more phosphorylation of c-jun than
the iOGN negative leukocytes, suggesting very distinct
phenotypic characteristics for these iOGN-positive innate
immune cells (Fig. 3f).
Glycosylation leads to different OGN variants
Because glycosylation is a very dynamic step that adds
glycans or glycosaminoglycans to proteins, we explored
whether the production of these different OGNs in the heart
(34, 50 and 72 kDa) originated from the single 32-kDa
protein backbone. Therefore, we treated protein lysates
with specific enzymes that are able to cleave the different
glycosaminoglycans or glycans. We found that the 50-kDa
OGN has N-linked glycans and N-linked keratan sulfate
attached (Fig. 4a). The addition of O-linked dermatan
sulfate resulted in the formation of the 34-kDa variant
(Fig. 4a). Furthermore, the addition of chondroitin sulfate
led to the formation of the 72-kDa variant, which is
potentially a dimer that could only be reduced by treatment
with all enzymes simultaneously (Fig. 4a). In brief, the
32-kDa protein core of OGN can be post-translationally
modified by either O- or N-linked glycosylation (Fig. 4b).
Interestingly, whereas the 72-kDa inflammatory OGN
(iOGN) variant was primarily located in the cell membrane
of both human peripheral leukocytes and murine bone
marrow-derived macrophages (BMDMs), the 34-kDa
fibrosis OGN (fOGN) was located in the cytosol, as
revealed by cell fractionation (Fig. 4c, e). Furthermore,
stimulation of BMDMs with lipopolysaccharides (LPS) not
only resulted in a significant increase in the transcript
levels of OGN (Fig. 4d), protein expression of the 72-kDa
iOGN membrane variant also increased in response to LPS
(Fig. 4e). Furthermore, the transcription and translation of
OGN were paralleled by an increased gene expression of
key glycosylation enzymes, such as Xylosyl transferase 2
(XYLT2) and D-glucuronyl C5-epimerase (Supplementary
Fig. 1). LPS thus increases the transcription, translation,
and glycosylation of OGN.
Membrane-bound inflammatory iOGN interacts
with TLR4 in leukocytes
Next, we sought to accurately understand the biological
role of the 72-kDa iOGN that was present on innate
immune cells where it was responsible for the apparent
‘‘active’’ phenotypic appearance of these cells. Given the
ability of leucine-rich repeats to interact with TLRs [12],
we speculated that this 72-kDa membrane-anchored
OGN might influence TLR signaling. In silico structure
modeling predicted a potential interaction between the
concave leucine-rich surface of OGN and the extracel-
lular LRR domain of TLR4 that has been implicated in
CVB3-myocarditis disease severity [13, 14] (Fig. 5a).
Therefore, HEK-BlueTM-mTLR cells containing an
inducible secreted embryonic alkaline phosphatase
(SEAP) reporter gene were stimulated with TLR-specific
ligands (Pam3CSK4 for TLR1/2, Poly(I:C) (HMW) for
TLR3, LPS-EK for TLR4, FLA-ST for TLR5, FLS-1 for
TLR6/2, and ODN1826 for TLR9) with and without
OGN knockdown (Supplementary Fig. 2A). OGN
knockdown significantly decreased TLR3, -4 and -5
signaling (Fig. 5b), supporting a possible interaction
between OGN and TLRs. Where several studies describe
the role of TLR4 during viral infection, as TLR4 is
upregulated in response to CVB3 inoculation on the
plasma membrane [5, 15] and contributes to its patho-
genesis [16], the contribution of especially TLR3 and
TLR5 is less founded [17]. Therefore, we focused on
investigating the interaction of OGN and TLR4 and
found that OGN co-immunoprecipitated with TLR4 in
both human peripheral leukocytes as well as in BMDM
lysates (Fig. 5c, d). In line with this observation,
immunofluorescence showed co-expression of OGN with
TLR4 on primary macrophages (Fig. 5e). Nevertheless, it
would be interesting to explore in a future study whether
there is overlap or specificity in OGN-TLR activity.
bFig. 3 72-kDa iOGN was found on cardiac and circulating innate
immune cells. aMurine cardiac monocytes/macrophages (Mac-3) and
neutrophils (Gr1) expressed OGN during CVB3-induced myocarditis.
b Circulating human monocytes and neutrophils also expressed OGN.
c Representative FACS plots of total human circulating leukocytes,
OGN-negative (OGN -ve), and -positive (OGN ?ve) circulating
leukocytes. d, e FACS analysis revealed that the OGN-positive
circulating leukocytes consisted mostly of neutrophils. f OGN-
positive circulating immune cells had increased phosphorylation of c
jun. n = 4, *p\ 0.001; all experiments were repeated at least twice.
Scale bar 50 lm
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As approximately 8 ± 2% of the human peripheral cir-
culating leukocytes expressing OGN on their surface appear
to be more ‘‘activated’’ (Fig. 4d–f), we wondered whether
this may be a consequence of augmented TLR4 signaling.
To validate the interaction of OGN with TLR4 in vivo, we
reasoned that a lack of OGN on circulating leukocytes in
OGN null mice, may alter TLR4 signaling in the mouse
model of endotoxemia. We, therefore, subjected OGN WT
and KOmice to endotoxemia, a model of septic shock where
TLR4 activation is, in part, driving pathogenesis. Although
mortality was severe in both genotypes, OGNWT mice died
earlier than their OGN-KO littermates (Table 1, p = 0.05;
Median survival: 8 h in WT versus 14 h in KO; ratio 0.5714
with 95% CI of 0.030–1.113). The serum levels of IL-12 and
IL-1b were also measured and significantly higher in OGN
WT mice than in their KO littermates 1 h after receiving an
intravenous dose of LPS (Table 1). Because only a small
subset of circulating leukocytes expressed iOGN, no clear
differences were found in the serum TNFa and IL-6 levels
(Table 1). Collectively, these findings suggest that iOGN
present on innate immune cells is crucial for boosting TLR4
activation.
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OGN promotes TLR4 activation resulting
in enhanced MAPK-induced cytokine production
As TLR4 activation leads to the expression of pro-in-
flammatory cytokines due to phosphorylation of many
downstream kinases, we wanted to confirm that the TLR4-
OGN interaction influenced TLR4 signaling. By stimulat-
ing isolated WT and KO macrophages with LPS, we first
analyzed TLR4 activation by determining pro-inflamma-
tory cytokine expression. The transcript levels of IL-6 and
TNFa were significantly increased in WT macrophages 1 h
after LPS stimulation (Fig. 6a, b), resulting in increased
protein levels of these cytokines in the medium 6 h after
stimulation (p\ 0.05, Fig. 6e, g). Concordantly, RNA
expression of IL-1b and IL-12 in OGN WT macrophages
was significantly higher 6 h after LPS stimulation (Fig. 6c,
d). Next, we examined whether OGN could influence the
phosphorylation of several kinases that are needed for
TLR4 activation. KO macrophages lacked the significant
MyD88 induction that was apparent in WT macrophages in
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Table 1 OGN boosts TLR4 activation in endotoxemia, a model of septic shock
WT (n = 23) KO (n = 22)
Median survival (h) 8 14 Ratio 0,57 (95% CI of ratio 0.03–1.11)
Log-rank (Mantel Cox) test
p = 0.05
TNFa (pg/ml) 5796 ± 570.5 5862 ± 505.1 p = 0.90
IL-6 (pg/ml) 56,191 ± 237.9 55,820 ± 294.4 p = 0.30
IL-12 (pg/ml) 396.3 ± 25.7 320 ± 24.4 p = 0.03
IL-1b (pg/ml) 17.5 ± 1.5 12,5 ± 1.4 p = 0.02
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response to LPS (p\ 0.001, Fig. 6f, h, Supplementary
Fig. 3 which includes 1 h after LPS stimulation). While the
baseline expression of pNFkB was greater in OGN-KO
macrophages, the induction was far less that in the WT
macrophages. Furthermore, a striking increase of c-jun
phosphorylation was found in response to LPS in WT
compared with KO macrophages, as a consequence of
increased MAPK phosphorylation (p\ 0.001, Fig. 6f, i–l).
Thus, our findings confirm that the interaction of OGN with
TLR4 increases phosphorylation c-jun which results in
more TLR4 activation and hence pro-inflammatory cyto-
kine expression (Fig. 8).
iOGN present on innate immune cells during viral
myocarditis aggravates cardiac inflammation
Next, we wondered whether the lack of this OGN–TLR4
interaction may influence cardiac inflammation as lack of
TLR4 signaling during viral myocarditis has previously
been associated with decreased cardiac inflammation
[16, 18]. Therefore, we subjected male OGN WT and KO
mice to the murine model of CVB3-induced myocarditis.
The absence of OGN in KO mice significantly reduced
cardiac immune cell infiltration relative to that of WT mice
7 days after viral exposure (8 ± 1.89% in OGN WT,
n = 11 vs 1.9 ± 0.4% in KO, n = 9; p = 0.01) (Fig. 7a,
b). More specifically, infiltration of leukocytes (CD45),
lymphocytes (CD3) and macrophages (Mac3) decreased in
the absence of OGN (Fig. 7c–f), supporting the pro-in-
flammatory role of OGN in myocarditis through enhanced
TLR4 signaling. Furthermore, while CVB3 viral levels and
immune cell recruitment were still similar in the heart at
day 4, IL-1b expression was already significantly increased
in the hearts of OGN WT animals, again supporting
enhanced TLR4 activation in the presence of iOGN
(Fig. 7g–i). In conclusion, the absence of OGN decreases
immune cell infiltration in CVB3-infected murine hearts,
suggesting that increased expression of leukocyte-specific
MyD88
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Fig. 6 OGN promotes TLR4 activation by enhancing MAPK-
induced cytokine production. Bone marrow-derived macrophages
(BMDMs) from WT and KO mice were isolated and stimulated with
LPS (10 ng/ml). a–d LPS stimulation resulted in the blunted
induction of pro-inflammatory cytokines TNFa and IL-6 expression
(1 h) as well as IL-1b and IL-12 at a later stage (6 h) (c, d). This
difference in TLR4 activation was reflected in the lower TNFa and
IL-6 expression levels in the medium of OGN-KO BMDMs (e, f).
This increased cytokine production was the result of significant
induction of MyD88 that was blunted in the OGN-KO BMDMs (g, h).
g Western blot analysis and further quantification revealed blunted
c-jun, ERK1/2 and JNK phosphorylation in the KO BMDMs, and
blunted pNFkB induction (i–l). All experiments were repeated at least
twice. n C 3; *p\ 0.05; **p\ 0.01; ***p\ 0.001
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72 kDa OGN in myocarditis aggravates cardiac inflam-
mation in the acute phase of myocarditis.
Discussion
This study has identified three major OGN variants that are
formed via either N- or O-linked glycosylation and corre-
lated with distinct pathophysiological processes. First, the
attachment of N-linked glycans and keratan sulfate to the
50-kDa OGN variant predominates in the eye, where it is
important for corneal transparency [3]. The smallest
34-kDa dermatan sulfate-OGN variant is highly abundant
in fibrotic tissues, as in cardiac infarct scars [9]. This
fibrotic dermatan sulfate-OGN (fOGN, 34 kDa) is needed
for proper collagen fibrillogenesis in the heart [7, 8], which
is in line with previous observations where dermatan
sulfate itself is involved in kidney fibrosis [19, 20]. Inter-
estingly, we uncovered a new O-linked chondroitin sulfate-
OGN variant (iOGN, 72-kDa) that is present in the mem-
brane of immune cells, where it binds and activates TLRs.
Chondroitin sulfate binding to the protein backbone of
OGN may result in putative dimerization as predicted in
silico by us and supported by previous studies for other
SLRPs [21, 22]. Collectively, these data indicate that a
matrix element can have distinct appearances and roles in
different disease contexts due to distinctive glycosylation,
significantly increasing our understanding of the versatile
nature of the ECM. Furthermore, as glycosylation is
important for the sorting and distribution of proteins within
the cell [23, 24], it may also explain the transportation of
OGN to either the cell membrane (iOGN) or extracellular
environment (fOGN). However, it is still unclear what
drives these protein glycosylation processes, as the serial
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Fig. 7 OGN increases cardiac inflammation in CVB3-induced
murine myocarditis. Analysis of H&E staining in OGN-KO mice
revealed significantly reduced cellular infiltration relative to WT mice
in human CVB3-induced viral myocarditis (a, scale: 1 mm top and
50 lm bottom) and b quantification (n C 11, **p\ 0.01). c De-
creased immune infiltration in OGN-KO mice was confirmed by the
reduced presence of CD45 positive leukocytes (d), CD3 positive
lymphocytes (e), and Mac3 positive macrophages (f). g Four days
after viral inoculation, the amount of immune cell infiltration was still
low and comparable in both genotypes (n C 4). h Viral levels
analyzed by RT-PCR were also comparable at this time. i Pro-
inflammatory cytokine IL-1b RNA expression, on the other hand, was
already significantly increased in WT compared with KO mice 4 days
after viral exposure. Scale 50 lm
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and mutual role of differentially expressed glycosylation
enzymes has not been completely elucidated. Hence, at
present, proper tools to study these spatio-temporal dif-
ferences in protein glycosylation are limited.
Nonetheless, we found that this 72-kDa iOGN is present
on innate immune cells in the heart and in the circulation,
where it can bind and activate TLR4 (Fig. 8). This acti-
vation results in an aggravated immune response in CVB3
induced viral myocarditis. Interestingly, there is no clear
co-localization of OGN with CD45 positive cells residing
in the healthy myocardium suggesting that they migrate
from the circulation into the heart upon injury. Even more,
the increased expression of IL-1b in the WT mice 4 days
after viral inoculation further supports the potential exag-
gerated immune response we see in OGN WT mice as a
consequence of enhanced TLR4 signaling. The clear
decrease in IL-1b and IL-18 levels in the heart of TLR4
deficient mice infected with CVB3 indicates that TLR4
signaling increases inflammation in the heart especially via
IL-1b induction [25, 26], and hence our interest in this
specific cytokine. This may, in part, explain the decreased
cardiac inflammation and necrosis in myocarditis in the
absence of OGN.
Our findings are in line with the previous studies,
revealing that distinct SLRPs, such as decorin and bigly-
can, directly stimulate TLRs [27, 28]. Moreover, it has
been speculated that SLRPs like biglycan may cluster
TLRs and influence their downstream signaling events
[29], though, where biglycan acts as direct endogenous
ligand of TLR4, OGN acts more like a co-receptor influ-
encing TLR4 signaling in the cell membrane. Aside from
influencing cardiac inflammation in viral myocarditis, the
interaction of OGN with TLR4 may also influence the
development and progression of other cardiac diseases.
Therefore, as TLR signaling contributes to the pathogen-
esis of ischemic myocardial injury [30–32], myocarditis
[31–33], septic cardiomyopathy [31–33], atherosclerosis
[31, 34] and, most importantly, the progression of heart
failure [31, 32], therapeutically modifying these receptors
seems promising. In patients, however, the results have
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Fig. 8 Schematic overview of the proposed iOGN:TLR4 signaling
pathway. TLR4 stimulation with LPS results in receptor dimerization
and subsequent high-affinity binding of the bridging adaptor
molecules TRAM and TIRAP. The bound and activated MyD88
then activates IRAK4, TRAF6, TAK1, and IKK complexes, and TRIF
signals through RIP1 to TRAF6/TAK1 and IKK. Both of these
pathways result in increased pro-inflammatory cytokine expression.
The phosphorylation of MAPKs by TAK1 is enhanced by OGN,
resulting in increased c-jun phosphorylation with subsequent nuclear
translocation of AP1 (the phosphorylated c-jun/c fos complex), which
again resulted in increased pro-inflammatory cytokine expression,
reinforcing the inflammatory response [47]
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been mixed. While, monoclonal antibodies against TLR2
(OPN-305) have been beneficial in reducing ischemia–
reperfusion injury in pigs [35] and are safe and well tol-
erated in healthy volunteers [36], they still need to be tested
in Phase II clinical trials. In comparison, despite promising
preclinical studies [37, 38], no clear benefit was identified
for the TLR4-specific antagonist Eritoran in elective car-
diac surgery patients in a Phase II, double-blind, placebo-
controlled study [39]. The failure of such studies empha-
sizes the complexity of TLR activation and highlights the
need to better understand the exact mechanisms utilized by
host-derived ligands [40]. Therefore, unraveling the com-
plete collection of exogenous and endogenous ligands in
the extracellular space that interact with TLRs is vital and
will help in comprehending their contribution to cardiac
inflammation in cardiac disease. Furthermore, since TLR3
is clearly implicated in immune activation in viral
myocarditis [41], exploration of OGN and TLR3 and 5
interactions is needed to unravel the precise effect of OGN
on cardiac inflammation in different cardiac diseases.
Finally, we found that in humans, iOGN was expressed
on migrated myocardial as well as circulating leukocytes,
where expression was found on macrophages and on a
subset of circulating neutrophils displaying a more pro-
inflammatory phenotype. This observed phenotype with
accompanying functional characteristics, therefore, may
contribute to the development of inflammatory cardiac
diseases, which has already been recognized for specific
neutrophil subsets during disease [15, 42].
In conclusion, we have identified for the first time that
SLRP OGN can be glycosylated in multiple ways, resulting
in the production a dermatan sulfate glycosylated variant
(fOGN) that is associated with fibrosis and a chondroitin
sulfate glycosylated membrane-bound variant (iOGN) that
is linked to inflammation. This iOGN is present in circu-
lating and cardiac innate immune cells where it boosts
TLR4 signaling, as in viral myocarditis and septic shock.
Materials and methods
Animals
C57Bl6/J male and female OGN-KO mice (backcrossed
more than 15 times) and WT mice in the same background
between 8 and 12 weeks of age were used in this study, and
all experiments were performed using age and sex-matched
groups. Mice were maintained in specific pathogen-free
facilities at Leuven University. All of the study protocols
were approved by the Animal Care and Use Committee of
the University of Leuven 243/2013. Experiments were
performed according to the official rules formulated in the
Belgian law on the care and use of experimental animals.
Murine CVB3-induced viral myocarditis model
Eight- to twelve-week old OGN-KO and WT mice were
inoculated by intraperitoneal (ip) injection of 1 9 107 cells
with a 50% infective dose (CCID50) of CVB3 (Nancy
Strain) diluted in 0.2 mL of saline on day 0. All animals
were anaesthetized with an ip injection of Xylazine
(10 mg/kg) and Ketamine (100 mg/kg) and sacrificed by
cervical dislocation 2, 4 or 7 days after CVB3 infection.
Organs were excised for further molecular and histological
analyses.
Endotoxic shock model and cytokine measurements
Age- and sex-matched OGN WT and KO mice between 6
and 12 weeks of age were given an ip injection of 40 mg of
D-galactosamine (200 ll) followed by an intravenous
injection of LPS (E. coli Ultrapure O111:B4, InvivoGen)
after 15 min. One hour later, whole blood was taken via
eye puncture, after which survival was monitored every
hour. After allowing the blood to clot by leaving it
undisturbed at room temperature for approximately
30 min, the clot was removed by centrifuging at
1000–2000g for 10 min in a refrigerated centrifuge. Serum
was stored at -20 C prior to cytokine measurements.
Cytokines were measured in serum and medium from
in vitro macrophage experiments using V-PLEX Pro-in-
flammatory Panel1 (mouse) Kit (K15048D-1) according to
the manufacturer’s protocol.
Staining and immunohistochemistry
Hearts were perfused from the apex with PBS, fixed
overnight in zinc fixative (BD Pharmingen, 550523) and
processed the following day prior to being embedded in
paraffin. The paraffin embedded left ventricle was cut
longitudinally in 4-lm sections and stained with hema-
toxylin and eosin (necrosis/inflammation) or Sirius red
F3BA (fibrosis).
Immunohistochemistry on zinc-fixed paraffin sections
was performed without using antigen retrieval according to
a protocol using antibodies against CD45 (BD Pharmingen;
1:200), Mac3 (Serotec MCAP497; 1:100), CD3 (Thermo
Scientific; 1:200), TLR4 (Abcam, ab22048), and OGN (for
human slides, Sigma HPA013132, 1:200; for murine slides,
US Biological O8062-05A, 1:100). Images were acquired
using the Leica Qwin image processing software (Leica,
Germany).
Western blotting and enzyme treatments
Tissues were lysed in RIPA SDS (50 mM Tris–HCl,
150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1%
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NP40, Proteinase Inhibitor Cocktail, Roche, 11697498001
and 0.5 mM orthovanadate), after which the protein con-
centration was determined using a Micro BCA Protein
assay kit (Thermo Scientific, Lot MJ162220). Samples
were diluted to a final concentration of 2 lg/ul, after which
two times sample buffer (25 ml 0.5 M Tris–HCl, 20 ml
100% glycerol, 20 ml, 20% SDS, 35 ml Aqua Dest with
1:10 b-Mercaptoethanol) was added to protein samples at a
1:1 ratio. Cells were directly lysed in sample buffer. For
western blot analyses, 20 lg of protein was loaded on a
10% gel (4 ml Aqua Dest, 3.3 ml 30% bisacrylamide,
2.5 ml 1.5 M Tris–HCl, pH 8.8, 0.1 ml 10% SDS,
0.004 ml TEMED). SDS PAGE was performed at 150 V
for approximately 90 min, after which the gel was trans-
ferred to a PVDF membrane by blotting at 200 mA for 2 h.
The membranes were blocked with 3.5% protifar (Nutricia)
for 1 h. Primary antibody was incubated overnight in 5%
BSA for osteoglycin (R&D, MAB2949), MyD88 (CTS,
#4283S) (p)NFkB (CTS #8242 and #3033), (p)PI3 K (CTS,
#4292, and #4228), (p)ERK1/2 (CTS, #9101S, and
#4695P), (p)JNK (CTS, #9251, and #9252), (p)p38 (CTS,
#4631S, and #9212), and (p)c-jun (CTS, #3270P, and
#9165P). Secondary antibodies conjugated with horse-
radish peroxidase (HRP) against rabbit (CTS, #7074S),
mouse (CTS, #7076S), or rat (Santa Cruz, E2313) were
next detected using enhanced chemi-luminescence, visu-
alized with an Artemis CCD Camera, and quantified using
ImageJ.
Enzyme treatments were carried out on macrophage cell
lysates that were lysed in RIPA SDS. After determining the
protein concentration of the sample with a Micro BCA
Protein assay kit, 10 lg of protein lysate (10 ll) was
denaturated by the addition of denaturation buffer (sup-
plied with PGNase; Bioke, P0705S) and heated for 3 min
at 100 C. Then, enzymes were added to the lysate and
incubated according to the standard protocol (PGNase,
Biolabs P0705S or Current Protocol in Molecular Biology,
17.13B 8). The enzymes used were Chondroitinase ABC
(Sigma, C3667), Endo-B-galactidase (Sigma, C6920),
Heparinase III (Sigma, H8891), Chondroitinase B (Sigma,
C8058), and PGNase (Bioke, P0705S). For every enzyme,
a control sample was incubated at the same temperature
and time. Finally, protein glycosylation was analyzed by
immunoblotting to determine size changes.
Structure and docking prediction
We used the I-TASSER Web service (MM1 [43], MM2
[44], and MM3 [45]) to predict the 3D structure of OGN
(on 2014-07-12). The default parameters for I-TASSER
were used. As an input sequence for OGN, the amino-acid
sequence from UniProt (Q62000) was used. The docking
prediction of TLR4 (PDB ID: 2Z64, chain A) and OGN
was calculated using the Hex Web service (MM4 [46]).
Again, the default parameters were used. Visualization of
the resulting structures was performed in Jmol (14.2.2,
http://www.jmol.org/).
Co-immunoprecipitation and cell fractionation
Fifty microliters of sheep anti-mouse M280 Dynabeads
(Invitrogen, 11201D) was prepared according to the man-
ufacturer’s protocol and incubated with either 4 lg of anti-
TLR4 (Abcam, ab22048) or 4 lg of normal mouse serum
(NMS; Sigma, M5905) in 50 ll for 2 h at 4 C. One bac-
terial plate with macrophages was lysed in PBS, spun down
for 10 min at 1200 rpm, and dissolved in 5 ml of IP buffer
(150 mM NaCl, 20 mM Tris–HCl, 5 mM EDTA, 1%
Triton ? Proteinase Inhibitor Cocktail, Roche,
11697498001) for 1 h at 4 C in a head-to-head rotator.
After determining the protein concentration (Thermo Sci-
entific, Lot MJ162220), 300 lg of protein lysate in 200 ll
of IP buffer was mixed with preincubated TLR4- or NMS-
sheep anti-mouse M280 Dynabeads overnight at 4 C. The
next day, the Dynabeads were washed three times and the
pellets were dissolved in 50 ll of 29 sample buffer. Pro-
teins were analyzed by western blotting as previously
described.
Cell fractionation was performed by lysing macrophages
that were seeded in 6-well plates (800,000 cells/well) in
200 ll of ice cold hypotonic lysis buffer (5 mM Tris–HCl,
pH 7.4, 5 mM NaCl, 2 mM EDTA, 1 mM CaCl2, 1 mM
MgCl2, 2 mM DTT ? Proteinase Inhibitor Cocktail,
Roche, 11697498001), after which they were spun down
for 1 h at max speed (13200 rpm) at 4 C. The pellet or
membrane fraction was dissolved in 50 ll of 29 sample
buffer. The cytosol fraction was dissolved 1:4 with 49
sample buffer, and twice the amount was loaded compared
with that of the membrane fraction. Proteins were analyzed
by western blotting as previously described.
HEK-Blue cell experiments
HEK-BlueTM mTLR4 reporting cells were purchased
through InvivoGen, were obtained by co-transfection of the
murine TLR4, MD-2 and CD14 co-receptor genes and an
inducible SEAP reporter gene into HEK293 cells (HEK-
BlueTM mTLR4, hkb-mtlr4, InvivoGen), and were cultured
according to the manufacturer’s protocol. As the SEAP
reporter gene was placed under the control of an IFN-b
minimal promoter fused to five NFjB and AP1-binding
sites, stimulation with a TLR4 ligand activates NFjB and
AP1, which induces the production of SEAP. SEAP pro-
duction was measured using QUANTI-Blue (QUANTI-
BlueTM, rep-qb1, InvivoGen) according to the manufac-
turer’s protocol. Cells were stimulated with either 2 or
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10 ng/ml LPS (Sigma), and all other TLR ligands (Mouse
TLR1-9 Agonist Kit, tlrl-kit1mw, InvivoGen; TLR-specific
ligands: Pam3CSK4 for TLR1/2, Poly(I:C) (HMW) for
TLR3, LPS-EK for TLR4, FLA-ST for TLR5, FLS-1 for
TLR6/2, and ODN1826 for TLR9) were stimulated at the
concentrations described in the manufacturer’s protocols.
Before stimulation, the cells were transfected with either
Silencer Negative Control siRNA (Life Technologies,
AM4611) or Silencer OGN siRNA (Life Technologies,
L-090181-01) using Lipopfectamine 2000 (Invitrogen,
11668-030) according to manufacturer’s protocol. Forty-
eight hours after transfection,0 the cells were seeded in
96-well plates and the TLR ligands were added.
Bone marrow-derived macrophage isolation
and experiments
Both tibias and femurs were collected from OGN WT and
KO mice in ice cold PBS and stripped of muscles. After
placing the stripped bones in 70% ethanol for approxi-
mately 45 s, they were again washed with PBS, after which
the ends were removed and the inner bone marrow was
flushed with a 25-G syringe filled with cold PBS. After
flushing all of the bones, a single-cell suspension was
obtained by pushing the suspension through a 100-lm
Nylon cell strainer. Cells were spun down at 1200 rpm,
placed in bacterial plates in RPMI 1640 with 15% LCM for
cell culture, and differentiated for approximately
8–10 days; medium was added or replaced every 2–3 days.
Experiments were performed after differentiation for
8–10 days. Cells were counted using a Burker Turk cell
counting chamber, and 400,000 cells were seeded in
12-well plates. The cells were stimulated the next day, after
the cells had adhered to the plastic, with 10 ng/ml LPS
(Sigma). At the end of the experiments, the cells were
directly harvested in RLT buffer for RNA isolation and
sample buffer for immunoblotting.
Human buffy coat preparation and Dynabead cell
isolation
Blood samples were collected using 5-ml BD Vacutainer
K2E (EDTA) tubes with erythrocyte lysis buffer (8.4 g
NH4Cl ? 0.84 g NaHCO3 in 1 L Aqua Dest, pH 7.2–7.4).
Blood was spun down at 200 g with the brake off for
20 min. Platelet-rich plasma was removed, after which the
cells were incubated for 3 min with 10 ml of ice cold
erythrocyte lysis buffer. Next, the cells were spun down at
1500 rpm for 10 min. Erythrocyte lysis was repeated if
erythrocytes were still present, because this would interfere
with Dynabead cell isolation. One hundred microliters of
Dynabeads M-280 Sheep Anti-Rabbit IgG (Invitrogen,
11203D) was incubated with 8 lg of anti-OGN antibody
(Sigma HPA013132) overnight at 48C according to the
manufacturer’s protocol in washing buffer [Ca2?- and
Mg2?-free phosphate buffered saline (PBS) supplemented
with 0.1% bovine serum albumin (BSA) and 2 mM EDTA
at pH 7.4]. The next day, the beads were washed three
times with washing buffer, after which they were incubated
with the buffy coat lysates. The buffy coat lysates were
washed twice with PBS with 0.1% BSA by centrifugation
at 225g for 8 min at 2–8 C and re-suspended at 1 9 108
cells/ml in PBS with 0.1% BSA. One milliliter of cell
suspension was incubated with 100 ll of beads at 2–8 C
for 30 min with gentle tilting and rotation. After washing
the bead-bound cells twice, they were re-suspended in
100 lL of buffer for FACS analysis. The term input is
referring to the complete human buffy coat samples that
were used. Addition of the OGN-bound beads removed all
OGN-positive leukocytes from these total buffy coats. The
remaining fraction was referred to as OGN-negative. All
fractions were analyzed by FACS. In addition, the phos-
phorylation of c-jun was determined by dissolving all
fractions in sample buffer, after determining total protein
content using Micro BCATM Protein Assay Kit (Life
Technologies, 23235)
Human samples
For Immunohistochemical analysis, histological section
was obtained from 16 patients suggestive of viral
myocarditis and of 14 post-mortem ‘healthy controls’
manually selected based on clinicopathological reports
from the host university hospital (Charite´, Berlin, Ger-
many) by an experienced pathologist (E. V.), who was not
involved in the preclinical data acquisition. The ethical
commission of Charite´ Germany approved the study. For
western blot analysis, human endomyocardial biopsy
samples suggestive of myocardial infarction of post-mor-
tem ‘healthy controls’ were manually selected based on
clinicopathological reports from the host university hospi-
tal (MUMC, Maastricht, The Netherlands) by an
experienced pathologist (E. V.), who was not involved in
the preclinical data acquisition. The ethical commission of
MUMC Maastricht approved the study.
Buffy coats for western blot analysis and flow cytometry
were collected from healthy volunteers after providing
proper informed consent.
Flow cytometry
Cells were stained with anti-CD3-FITC, CD66b-FITC,
CD19-FITC, CD19-BV421, CD56-PE, and HLA-DR-V55
(BD Biosciences), and measured with FACS-Canto II (BD
Biosciences). Results were analyzed with the FACSdiva
software (BD Biosciences).
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RT-PCR
Real-time reverse transcriptase-polymerase chain reaction
(RT-PCR) analysis was performed (Bio-Rad, Maastricht,
The Netherlands) to determine the transcript levels of the
following genes:
CVB3 forward primer ACGAATCCCAGT
GTGTTTTGG
reverse primer TGCTCAAAAACG
GTATGGACAT at 63.9 C;
IL-6 forward primer CAAAGCCAGAGT
CCTTCAGAG
reverse primer GCCACTCCTTCTG
TGACTCC at 63.9 C;
TNFa forward primer CCACCACGCTCT
TCTGTCTA
reverse primer AGGGTCTGGGCC
ATAGAACT at 63.9 C;
IL-1b forward primer GTAATGAAAGAC
GGCACACC
reverse primer TACCAGTTGGGG
AACTCTGC at 63.9 C;
IL-12 forward primer CTAGACAAGGGC
ATGCTGGT
reverse primer TCTCCCACAGGA
GGTTTCTG at 63.9 C;
OGN forward primer CCTGGAATCTGT
GCCTCCTA
reverse primer TCCAGGCGAATC
TCTTCAAT at 63.9 C;
XYLT2 forward primer AGAGTCTGGAGG
TTGGTACTGAG
reverse primer GCTACGGGCTCA
TCCAGTG at 61 C;
GlcNact forward primer GCTACTTCTAGA
ACCATTCTTGTCA
reverse primer GCATAAGTTTCG
TTGGTTCTGT at 61 C;
Gsgalnact forward primer GACTCGCCGAGG
CTTTACTC
reverse primer AGTCATAGCCCC
AAAGTGGC at 61 C;
Gluc-C5-Epimerase forward primer GTGGAGTTGAAG
GTGTGCCA
reverse primer GTGAGGGGGTTT
CTCGGTTA at 61 C;
GAPDH forward primer GGTGGACCTCAT
GGCCTACA
reverse primer CTCTCTTGCTCAG
TGTCCTTGCT at 63.9 C.
The primer sequences of these genes were determined
by the NCBI software analysis of Primer BLAST. The
details of the sequences and thermal cycling conditions
were according to the standard protocol. Data were
acquired and analyzed with the IQ5 software (Bio-Rad,
Maastricht, The Netherlands).
Statistical analysis
The results represent the mean ± SEM unless otherwise
indicated. For murine studies, D’Agistino and Pearson’s
omnibus normality test was performed. Statistical signifi-
cance was determined by unpaired Student’s t test and one-
way ANOVA when the data were normally distributed.
Wilcoxon, Mann–Whitney, and Kruskal–Wallis tests with
Dunn’s multiple comparison tests were used for non-
parametric data as indicated. The Gehan–Breslow–Wil-
coxon test was used for survival analysis. Statistical
analyses were performed with the GraphPad Prism soft-
ware v5.0 with *p\ 0.05, **p\ 0.01, and ***p\ 0.001.
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